San Diego biotech Halozyme Therapeutics Inc. said it will collaborate with Genentech, a member of the Roche Group, to evaluate how a combination of the two firms’ products affect up to eight tumor types in clinical studies next year.
The first study, led by Genentech, will be a Phase 1b/2 trial to evaluate how Genentech’s cancer immunotherapy, Tecentriq, works when used with Halozyme’s investigational drug, PEGPH20. Halozyme will supply the drug for this study.
The second study will be a Phase 1b trial led by Halozyme to asses Tecentriq when used with both PEGPH20 and chemotherapy in bile duct cancer and gallbladder cancers.
Halozyme’s lead product, PEGPH20, is already in multiple clinical trials for varyious types of cancer.
Following the data that will come from these new studies, Halozyme may scale the clinical trials to meet standards required for new drug registration with the U.S. Food and Drug Administration.
Financial details of the collaboration were not disclosed.
